Recent Updates
Recently added Catalysts

PF-07940367

Phase 1

Healthy | Small molecule | Other |Pfizer, Inc.|Last Updated: Jun 13, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedCONTROLLED
Total Trials1
Total Enrollment40

FDA Designations

No designations recorded

Clinical trial landscape

PF-07940367 · 1 trial · 1 indication

Phase 1 1
NCT06190561A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy AdultsHealthy
COMPLETED40 Analytics
PHASE1COMPLETED
A Study to Learn How Different Products of the Study Medicine Called PF-07940367 Are Taken up Into the Blood in Healthy Adults
Healthy
NCT0619056140
Unlock trial analytics

Study Endpoints

Primary Endpoints

Area under the whole blood concentration versus time curve (AUC) from time zero (pre-dose) to 336 hours (AUC336) of PF-07940367 dose to evaluate pharmacokinetic comparability of two PF-07940367 products
0 hours (pre-dose) to 336 hours post-PF-07940367 dose

Secondary Endpoints

Number of Participants With Treatment-Emergent Adverse Events (AEs)
From baseline up to 56 days after PF-07940367 dose
Number of Participants With Clinically Significant Laboratory Abnormalities
From baseline up to 336 hours after PF-07940367 dose
Number of Participants With Clinically Significant Electrocardiogram (ECG) Findings
From baseline up to 96 hours after PF-07940367 dose
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Treatment A: PF-07940367 Product IIEXPERIMENTALtablet by mouth
Treatment B: PF-07940367 Product IEXPERIMENTALtablet by mouth

Interventions

NameTypeDescription
PF-07940367DRUGParticipants to receive a single dose of PF-07940367 product II 150 mg by mouth
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring. * BMI of 16-32 kg/m2; and a total body weight \>50 kg (110 lb). * Willing and able to comply with...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about PF-07940367

What is PF-07940367?

PF-07940367 is an investigational small molecule being developed by Pfizer, Inc. It is currently in Phase 1 clinical development. The drug is being studied in healthy adults to understand how different formulations are taken up into the blood. It is not approved and remains in clinical trials.

What is PF-07940367 used for?

PF-07940367 is being studied for use in healthy adults. The ongoing clinical research focuses on how the drug is absorbed into the bloodstream. It is an investigational product and has not been approved for any medical condition.

Who makes PF-07940367?

PF-07940367 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The company is conducting clinical trials to evaluate the drug's absorption in healthy adults.

What phase is PF-07940367 in?

PF-07940367 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug remains under evaluation.

What clinical trials is PF-07940367 in?

PF-07940367 has one completed Phase 1 clinical trial, identified as NCT06190561. This study enrolled 40 healthy adults in the United States to evaluate how different formulations of the drug are absorbed into the blood. The trial was controlled but not double-blinded.

Is PF-07940367 FDA approved?

PF-07940367 is not FDA approved. It is an investigational drug currently in Phase 1 clinical development. The completed trial, NCT06190561, studied the drug's absorption in healthy adults, but it has not been approved for any use.